Erythropoietin Stimulates Tumor Growth via EphB4

Cancer Cell

Volumn 28, Issue 5, 2015, Pages 610-622

  Pradeep, Sunila ^a   Huang, Jie ^a   Mora, Edna M ^a,b,c   Nick, Alpa M ^a   Cho, Min Soon ^a   Wu, Sherry Y ^a   Noh, Kyunghee ^a   Pecot, Chad V ^d   Rupaimoole, Rajesha ^a   Stein, Martin A ^e   Brock, Stephan ^e   Wen, Yunfei ^a   Xiong, Chiyi ^a   Gharpure, Kshipra ^a   Hansen, Jean M ^a   Nagaraja, Archana S ^a   Previs, Rebecca A ^a   Vivas Mejia, Pablo ^b   Han, Hee Dong ^a   Hu, Wei ^a   Mangala, Lingegowda S ^a   Zand, Behrouz ^a   Stagg, Loren J ^a   Ladbury, John E ^a   Ozpolat, Bulent ^a   Alpay, S Neslihan ^a   Nishimura, Masato ^a   Stone, Rebecca L ^a   Matsuo, Koji ^a   Armaiz Peña, Guillermo N ^a   Dalton, Heather J ^a   Danes, Christopher ^a   Goodman, Blake ^a   Rodriguez Aguayo, Cristian ^a   Kruger, Carola ^f   Schneider, Armin ^f   Haghpeykar, Shyon ^a   Jaladurgam, Padmavathi ^a   Hung, Mien Chie ^a,g   Coleman, Robert L ^a   Liu, Jinsong ^a   Li, Chun ^a   Urbauer, Diana ^a   Lopez Berestein, Gabriel ^a   Jackson, David B ^e   Sood, Anil K ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

^c UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e Experimental Medicine GmbH   (Germany)

^f SYGNIS Pharma AG   (Germany)

^g CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

EPHRIN RECEPTOR B4; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; RECOMBINANT ERYTHROPOIETIN; STAT3 PROTEIN; PROTEIN BINDING; RECOMBINANT PROTEIN;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER PROGNOSIS; CARCINOGENESIS; CELL INVASION; CLINICAL STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; COS 1 CELL LINE; DISEASE SPECIFIC SURVIVAL; DRUG EFFECT; ENDOTHELIUM CELL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; STATISTICAL ANALYSIS; TUMOR GROWTH; ANIMAL; BREAST TUMOR; C57BL MOUSE; DISEASE COURSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; MCF-7 CELL LINE; METABOLISM; MIDDLE AGED; NUDE MOUSE; OVARY TUMOR; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; VERY ELDERLY; WESTERN BLOTTING; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; DISEASE PROGRESSION; ERYTHROPOIETIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MCF-7 CELLS; MICE, INBRED C57BL; MICE, NUDE; MIDDLE AGED; OVARIAN NEOPLASMS; PROTEIN BINDING; RECEPTOR, EPHB4; RECEPTORS, ERYTHROPOIETIN; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STAT3 TRANSCRIPTION FACTOR; YOUNG ADULT;

EID: 84946552470     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2015.09.008     Document Type: Article

References (48)

1. Aapro M., Jelkmann W., Constantinescu S.N., Leyland-Jones B. Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer. Br. J. Cancer 2012, 106:1249-1258.
2. Ahmed A.A., Lu Z., Jennings N.B., Etemadmoghadam D., Capalbo L., Jacamo R.O., Barbosa-Morais N., Le X.F., Vivas-Mejia P., Lopez-Berestein G., et al. SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer. Cancer Cell 2010, 18:109-121.
3. Authier F., Desbuquois B. Glucagon receptors. Cell. Mol. Life Sci. 2008, 65:1880-1899.
4. Belda-Iniesta C., Perona R., Carpeño Jde.C., Cejas P., Casado E., Manguan-García C., Ibanez de Caceres I., Sanchez-Perez I., Andreu F.B., Ferreira J.A., et al. Human recombinant erythropoietin does not promote cancer growth in presence of functional receptors expressed in cancer cells. Cancer Biol. Ther. 2007, 6:1600-1605.
5. Brines M., Cerami A. The receptor that tames the innate immune response. Mol. Med. 2012, 18:486-496.
6. Brines M., Patel N.S., Villa P., Brines C., Mennini T., De Paola M., Erbayraktar Z., Erbayraktar S., Sepodes B., Thiemermann C., et al. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc. Natl. Acad. Sci. USA 2008, 105:10925-10930.
7. Chang Y.S., Mu D., Wendland M., Sheldon R.A., Vexler Z.S., McQuillen P.S., Ferriero D.M. Erythropoietin improves functional and histological outcome in neonatal stroke. Pediatr. Res. 2005, 58:106-111.
8. Chateauvieux S., Grigorakaki C., Morceau F., Dicato M., Diederich M. Erythropoietin, erythropoiesis and beyond. Biochem. Pharmacol. 2011, 82:1291-1303.
9. Chen J., Connor K.M., Aderman C.M., Willett K.L., Aspegren O.P., Smith L.E. Suppression of retinal neovascularization by erythropoietin siRNA in a mouse model of proliferative retinopathy. Invest. Ophthalmol. Vis. Sci. 2009, 50:1329-1335.
10. *ephrinB2 protein-protein interaction and receptor specificity. J. Biol. Chem. 2006, 281:28185-28192.
11. Chrencik J.E., Brooun A., Recht M.I., Kraus M.L., Koolpe M., Kolatkar A.R., Bruce R.H., Martiny-Baron G., Widmer H., Pasquale E.B., Kuhn P. Structure and thermodynamic characterization of the EphB4/Ephrin-B2 antagonist peptide complex reveals the determinants for receptor specificity. Structure 2006, 14:321-330.
12. Crouch Z., DeSantis E.R. Use of erythropoietin-stimulating agents in breast cancer patients: a risk review. Am. J. Health Syst. Pharm. 2009, 66:1180-1185.
13. Davies M.H., Zamora D.O., Smith J.R., Powers M.R. Soluble ephrin-B2 mediates apoptosis in retinal neovascularization and in endothelial cells. Microvasc. Res. 2009, 77:382-386.
14. Foley R.N. Erythropoietin: physiology and molecular mechanisms. Heart Fail. Rev. 2008, 13:405-414.
15. Glaspy J. Hematology: ESAs to treat anemia--balancing the risks and benefits. Nat. Rev. Clin. Oncol. 2009, 6:500-502.
16. Glaspy J.A. Erythropoietin in cancer patients. Annu. Rev. Med. 2009, 60:181-192.
17. Halder J., Landen C.N., Lutgendorf S.K., Li Y., Jennings N.B., Fan D., Nelkin G.M., Schmandt R., Schaller M.D., Sood A.K. Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells. Clin. Cancer Res. 2005, 11:8829-8836.
18. Han L.Y., Fletcher M.S., Urbauer D.L., Mueller P., Landen C.N., Kamat A.A., Lin Y.G., Merritt W.M., Spannuth W.A., Deavers M.T., et al. HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma. Clin. Cancer Res. 2008, 14:3372-3379.
19. Hedley B.D., Allan A.L., Xenocostas A. The role of erythropoietin and erythropoiesis-stimulating agents in tumor progression. Clin. Cancer Res. 2011, 17:6373-6380.
20. Hutchinson S.L., Wooldridge L., Tafuro S., Laugel B., Glick M., Boulter J.M., Jakobsen B.K., Price D.A., Sewell A.K. The CD8 T cell coreceptor exhibits disproportionate biological activity at extremely low binding affinities. J. Biol. Chem. 2003, 278:24285-24293.
21. Jerabek-Willemsen M., Wienken C.J., Braun D., Baaske P., Duhr S. Molecular interaction studies using microscale thermophoresis. Assay Drug Dev. Technol. 2011, 9:342-353.
22. Kassem L.A., Yassin N.A. Role of erythropoeitin in prevention of chemotherapy-induced peripheral neuropathy. Pak. J. Biol. Sci. 2010, 13:577-587.
23. Krosl J., Damen J.E., Krystal G., Humphries R.K. Interleukin-3 (IL-3) inhibits erythropoietin-induced differentiation in Ba/F3 cells via the IL-3 receptor alpha subunit. J. Biol. Chem. 1996, 271:27432-27437.
24. Kumar S.M., Zhang G., Bastian B.C., Arcasoy M.O., Karande P., Pushparajan A., Acs G., Xu X. Erythropoietin receptor contributes to melanoma cell survival in vivo. Oncogene 2012, 31:1649-1660.
25. Leist M., Ghezzi P., Grasso G., Bianchi R., Villa P., Fratelli M., Savino C., Bianchi M., Nielsen J., Gerwien J., et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004, 305:239-242.
26. Lu C., Han H.D., Mangala L.S., Ali-Fehmi R., Newton C.S., Ozbun L., Armaiz-Pena G.N., Hu W., Stone R.L., Munkarah A., et al. Regulation of tumor angiogenesis by EZH2. Cancer Cell 2010, 18:185-197.
27. Mason J.C., Tager H.S. Identification of distinct receptor complexes that account for high-and low-affinity glucagon binding to hepatic plasma membranes. Proc. Natl. Acad. Sci. USA 1985, 82:6835-6839.
28. McCarty K.S., Miller L.S., Cox E.B., Konrath J., McCarty K.S. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch. Pathol. Lab. Med. 1985, 109:716-721.
29. McKinney M., Arcasoy M.O. Erythropoietin for oncology supportive care. Exp. Cell Res. 2011, 317:1246-1254.
30. McMahon F.G., Vargas R., Ryan M., Jain A.K., Abels R.I., Perry B., Smith I.L. Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers. Blood 1990, 76:1718-1722.
31. Merritt W.M., Lin Y.G., Han L.Y., Kamat A.A., Spannuth W.A., Schmandt R., Urbauer D., Pennacchio L.A., Cheng J.F., Nick A.M., et al. Dicer, Drosha, and outcomes in patients with ovarian cancer. N. Engl. J. Med. 2008, 359:2641-2650.
32. Merritt W.M., Lin Y.G., Spannuth W.A., Fletcher M.S., Kamat A.A., Han L.Y., Landen C.N., Jennings N., De Geest K., Langley R.R., et al. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J. Natl. Cancer Inst. 2008, 100:359-372.
33. Noguchi C.T., Asavaritikrai P., Teng R., Jia Y. Role of erythropoietin in the brain. Crit. Rev. Oncol. Hematol. 2007, 64:159-171.
34. Okazaki T., Ebihara S., Asada M., Yamanda S., Niu K., Arai H. Erythropoietin promotes the growth of tumors lacking its receptor and decreases survival of tumor-bearing mice by enhancing angiogenesis. Neoplasia 2008, 10:932-939.
35. Olsson-Gisleskog P., Jacqmin P., Perez-Ruixo J.J. Population pharmacokinetics meta-analysis of recombinant human erythropoietin in healthy subjects. Clin. Pharmacokinet. 2007, 46:159-173.
36. Pradeep S., Kim S.W., Wu S.Y., Nishimura M., Chaluvally-Raghavan P., Miyake T., Pecot C.V., Kim S.J., Choi H.J., Bischoff F.Z., et al. Hematogenous metastasis of ovarian cancer: rethinking mode of spread. Cancer Cell 2014, 26:77-91.
37. Rathod D.B., Salahudeen A.K. Nonerythropoietic properties of erythropoietin: implication for tissue protection. J. Investig. Med. 2011, 59:1083-1085.
38. Rupaimoole R., Wu S.Y., Pradeep S., Ivan C., Pecot C.V., Gharpure K.M., Nagaraja A.S., Armaiz-Pena G.N., McGuire M., Zand B., et al. Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression. Nat. Commun. 2014, 5:5202.
39. Salvucci O., de la Luz Sierra M., Martina J.A., McCormick P.J., Tosato G. EphB2 and EphB4 receptors forward signaling promotes SDF-1-induced endothelial cell chemotaxis and branching remodeling. Blood 2006, 108:2914-2922.
40. Sturm B., Helminger M., Steinkellner H., Heidari M.M., Goldenberg H., Scheiber-Mojdehkar B. Carbamylated erythropoietin increases frataxin independent from the erythropoietin receptor. Eur. J. Clin. Invest. 2010, 40:561-565.
41. Syed R.S., Reid S.W., Li C., Cheetham J.C., Aoki K.H., Liu B., Zhan H., Osslund T.D., Chirino A.J., Zhang J., et al. Efficiency of signalling through cytokine receptors depends critically on receptor orientation. Nature 1998, 395:511-516.
42. Sytkowski A.J. Does erythropoietin have a dark side? Epo signaling and cancer cells. Sci. STKE 2007, 2007:pe38.
43. Thaker P.H., Han L.Y., Kamat A.A., Arevalo J.M., Takahashi R., Lu C., Jennings N.B., Armaiz-Pena G., Bankson J.A., Ravoori M., et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat. Med. 2006, 12:939-944.
44. Tóvári J., Pirker R., Tímár J., Ostoros G., Kovács G., Döme B. Erythropoietin in cancer: an update. Curr. Mol. Med. 2008, 8:481-491.
45. Uhlén M., Fagerberg L., Hallström B.M., Lindskog C., Oksvold P., Mardinoglu A., Sivertsson Å., Kampf C., Sjöstedt E., Asplund A., et al. Proteomics. Tissue-based map of the human proteome. Science 2015, 347:1260419.
46. Wang L., Li H.G., Xia Z.S., Wen J.M., Lv J. Prognostic significance of erythropoietin and erythropoietin receptor in gastric adenocarcinoma. World J. Gastroenterol. 2011, 17:3933-3940.
47. Wu S.Y., Yang X., Gharpure K.M., Hatakeyama H., Egli M., McGuire M.H., Nagaraja A.S., Miyake T.M., Rupaimoole R., Pecot C.V., et al. 2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. Nat. Commun. 2014, 5:3459.
48. Zamora D.O., Davies M.H., Planck S.R., Rosenbaum J.T., Powers M.R. Soluble forms of EphrinB2 and EphB4 reduce retinal neovascularization in a model of proliferative retinopathy. Invest. Ophthalmol. Vis. Sci. 2005, 46:2175-2182.